It's 2024 and women are still making less money than men. Photo by LinkedIn Sales Solutions on Unsplash

It's 2024 and women are still making less money than men, thus keeping the unfortunate reality of the wage gap alive. But at least in Houston, the wage gap isn't as bad as other Texas cities, according to a new earnings study by Chamber of Commerce.

Houston ranked No. 142 on the list, which examined earnings for full-time workers in 170 of the most populous cities in the United States.

The study found that, in 2024, men in Houston are currently making $4,474 more than women — a figure that's significantly lower than the national wage gap, which is a little over $11,000.

The U.S. city with the worst gender pay gap is none other than Frisco, a Dallas suburb. Men in Frisco are currently making a staggering $52,216 more than women, which is more than $12,000 more than the gap in 2023.

Also in North Texas, McKinney remained in the No. 5 spot for the second consecutive year. McKinney men make $24,568 more than women, which is a $4,400 decrease year-over-year. Plano's gender wage gap has worsened since 2023: The Dallas suburb is now listed among the top 10 worst pay gaps in the U.S., climbing to No. 6. The study says the Plano's wage gap is now $23,415, or nearly $2,300 more than last year.

Statewide gender pay gap

Chamber of Commerce found that Texas' gender pay gap has increased since last year; The 2023 study found that women made nearly $11,000 less than men, and that discrepancy has widened in 2024 to nearly $12,000.

However, Texas' ranking has improved 10 spots from No. 29 last year to No. 19 this year.

For added context, New Hampshire has the No. 1 worst pay gap in the nation, with men making over $18,000 more than women.

Other Texas cities that earned spots in the report are:

  • No. 20 – Amarillo
  • No. 22 – Laredo
  • No. 24 – Austin
  • No. 30 – Corpus Christi
  • No. 31 – Pasadena
  • No. 33 – Irving
  • No. 52 – Lubbock
  • No. 59 – El Paso
  • No. 65 – Grand Prairie
  • No. 81 – Fort Worth
  • No. 118 – Dallas
  • No. 121 – San Antonio
  • No. 125 – Arlington
  • No. 167 – Brownsville
  • No. 168 – Garland

------

This article originally ran on CultureMap.

A new study finds how Houston — and other Texas cities — rank in terms of the pay gap between male and female workers. Photo via Getty Images

How Houston stacks up when it comes to its gender pay gap

mind the gap

Pi wasn't the only thing celebrated yesterday on March 14. Equal Pay Day is also celebrated on the same day — a day to examine the decades of advocacy to extinguish the pay gap between men and women.

Unfortunately, nationwide the gap is still large. The latest Census Bureau says women make 18 percent less money than men do. We know the numbers for Texas and several of its cities, thanks to a new study by small biz experts Chamber of Commerce. They investigated the earnings for full-time workers in 170 of the most populous cities in the United States.

The analysis found that Texas has the 29th largest pay gap out of all 50 states, with women making nearly $11,000 less than men. Texas women can be glad they don’t live in Wyoming, which has the largest pay gap of the states at almost $19,000.

The city with the largest gender pay gap in the United States is Sunnyvale, California, home to Silicon Valley, with an earnings difference of $40,584 between men and women. Actually, California cities make up half of the top 10 largest gender pay gaps.

Texas, however, has two towns in the top 10. Coming in at No. 2 is Frisco and McKinney lands at No. 5. Frisco men make nearly $40,000 more than women, while McKinney men make $29,000 more than women. Just outside the top 10 is Plano at No. 12, with their gender pay gap adding up to $20,736.

How does Houston fair? Not too shabby, actually. The Bayou City landed at the No. 114 spot out of 170 of the most-populated cities in the U.S. Dallas actually has the smallest gender pay gap in Texas, coming in at No. 166 with just $192 between full-time working men and women.

Here's how the rest of Texas ranks:

  • No. 13 – Austin
  • No. 25 – Pasadena
  • No. 30 – Lubbock
  • No. 45 – Fort Worth
  • No. 70 – Irving
  • No. 71 – Corpus Christi
  • No. 74 – San Antonio
  • No. 89 – Arlington
  • No. 93 – Grand Prairie
  • No 97 – El Paso
  • No. 101 – Laredo
  • No. 110 – Amarillo
  • No. 125 – Brownsville
  • No. 134 – Garland

The full study can be found on chamberofcommerce.org.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”